Vifor pays $110M upfront for EU rights to late-phase renal disease drugs – FierceBiotech

Vifor pays $110M upfront for EU rights to late-phase renal disease drugs – FierceBiotech

Vifor pays $110M upfront for EU rights to late-phase renal disease drugs – FierceBiotech
Published on 2016-05-11